IHL-675A
Inflammatory Conditions (Rheumatoid Arthritis/Lung Inflammation)
PreclinicalPreclinical completed
Key Facts
Indication
Inflammatory Conditions (Rheumatoid Arthritis/Lung Inflammation)
Phase
Preclinical
Status
Preclinical completed
Company
About Incannex Healthcare
Incannex Healthcare is advancing a diversified portfolio of drug candidates that combine cannabinoids, psychedelics, and other novel compounds to address complex disorders with limited treatment options. The company has established a robust clinical development pathway with several programs in Phase 2 trials and strategic research collaborations. Incannex leverages its Australian base to access global markets through NASDAQ listing (IXHL) while pursuing FDA regulatory pathways for its most advanced candidates.
View full company profile